Phase II
BioSpace put together a list of the top 10 indications being researched in the area by pharma companies, academic institutions and other organizations.
As the 61st American Society of Hematology Annual Meeting wrapped up in Orlando, Florida, there were hundreds of studies and results presented. Here’s a look at some.
Under a Technology License Agreement with the Houston Methodist Research Institute, Contract Developer and Manufacturer VGXI Achieves Key Milestones with Establishment of Pilot Production Capabilities for RNA-Based Medicines.
The primary efficacy endpoint was change in best corrected visual acuity (BCVA) at 16 weeks compared to sham (placebo) treatment.
When Bristol-Myers Squibb acquired Celgene this year for $74 billion, one of the drugs it picked up was a CAR-T therapy, lisocabtagene maraleucel (liso-cel).
It was, as usual, a pretty busy week in clinical trial news. Here’s a look.
Over the course of the past year, Novartis has seen significant success with the approval of five drugs that have blockbuster potential and the company sees an additional 25 potential blockbuster drugs in its pipeline.
Shares of France-based Ipsen are down more than 2% on the Euronext Paris exchange after the U.S. Food and Drug Administration placed a partial clinical hold on its investigational treatment for fibrodysplasia ossificans progressiva (FOP) and multiple osteochondromas (MO).
Even with a shortened week due to the U.S. Thanksgiving holiday, there was plenty of clinical trial news and updates. Here’s a look.
Combination of Prexigebersen and Decitabine Showed Encouraging Safety and Efficacy Results
PRESS RELEASES